Hengrui 1 class of innovative anesthetics, rimazolom toluene sulfonate for injection is on the market!

Recently, the State Drug Administration approved Jiangsu Hengrui Pharmaceutical Co., Ltd.'s class 1 innovative drug, rimazolen toluene sulfonate for injection (trade name: ribinine), through the priority review and approval process, for sedation of routine gastroscopy Ramazolam toluene sulfonate is a benzodiazepine, which acts on GABAA receptor It is an innovative drug independently researched and developed in China and has independent intellectual property rights The marketing of rimazazolam for injection will provide a new choice for sedation by routine gastroscopy In addition, the State Drug Administration, the Ministry of public security and the national health and Health Commission, in accordance with the relevant provisions of the regulations on the administration of narcotic drugs and psychotropic substances, decided to list rimazolen (including its possible salts, unilateral preparations and isomers) into the second category of psychotropic drugs management, which will be implemented from January 1, 2020 Due to the aging population and the improvement of people's health awareness, the volume of endoscopy in China is increasing year by year, the volume of in-hospital surgery is increasing, and driven by new domestic varieties, the growth rate of intravenous anesthesia market in China is bound to accelerate in the future It is predicted that ramazolam will be the new profit growth point of Hengrui anesthesia line after listing Adorable adorable